Drug intelligence / Profile preview

LC106

Development stage: Phase 1
Lead developer: Biose Industrie
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Vaginal

Overview

**LC106** is an investigational vaginal live biotherapeutic product consisting of six strains of *Lactobacillus crispatus*, formulated as a vaginal tablet at 2 × 10^9 colony-forming units per dose. It is being evaluated following oral metronidazole therapy for bacterial vaginosis, with the intended effect of establishing durable vaginal colonization by beneficial *L. crispatus* strains and restoring a Lactobacillus-predominant vaginal microbiome. LC106 was studied in the Phase 1 VIBRANT trial and is also being evaluated in a clinician-administered follow-on study of colonization kinetics. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2451865425001280))

Beyond the preview

Go deeper on LC106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC106.

Explore the full profile